University of Sheffield spinout company, Rinri Therapeutics, has raised a total of £10 million from investors and the UK Future Fund to advance its novel stem cell therapy to restore hearing loss.

The biotechnology company is developing a novel stem cell therapy to restore hearing and will use the £10 million raised from existing investors, Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund, to support the development of its novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

Rinri’s underlying technology is based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield. It seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. 

Read more.

Categories: Industry News